The trial showed that oral VA106483 was successful in producing a predictable and sustained anti-diuretic effect in nocturia patients, as determined by increased osmolality and decreased urine output.
Rexahn has signed an exclusive collaboration and option for license agreement with the Partner Co., for the development of RX-3117. RX-3117 is a small molecule, new chemical entity
Abraxis has received a recommendation from the Quebec Conseil du Medicament and approval from the Quebec Ministry of Health for Abraxane, for Injectable Suspension 100mg in Quebec. It
Access has commenced commercial launch of MuGard in Greece. Under a license from Access, SpePharm is responsible for manufacturing, regulatory approval and commercialization in 27 countries of Europe.
Amarillo (ABI) and CytoPharm have started the enrollment for a study of ABI’s oral interferon-alpha lozenges, for chronic hepatitis-C virus infection. The aim of the trial is to
Hospira has received FDA approval for a 500mg vial of azithromycin for injection, in the ADD-Vantage System. The anti-infective medication is a generic version of Pfizer’s Zithromax for
Teva and its partner, Antares have received approval of a Supplemental New Drug Application (sNDA), which added needle-free injection to its Tev-Tropin, human growth hormone (hGH) drug label.
Novartis has initiated phase-III clinical study with NVA237, a once-daily, muscarinic antagonist (Lama), for the treatment of chronic obstructive pulmonary disease (COPD). NVA237 is a dry powder formulation
Juvaris has signed an agreement with Antigen Discovery (ADi) to access ADi’s high-throughput protein microarray screening system to discover novel disease-specific antigens. Juvaris will sponsor research for multiple
Cordex has completed the production of the ATPace clinical trial material (CTM), in preparation for planned pivotal clinical trials. The protocol of these clinical trials has been approved
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.